NYSEAMERICAN:NAVB

Navidea Biopharmaceuticals - NAVB Stock Forecast, Price & News

$0.32

+0.04 (+14.29%)

(As of 03/30/2023 04:00 PM ET)

Add

Compare

Today's Range: $0.28
▼
$0.33
50-Day Range: N/A
52-Week Range: $0.16
▼
$1.24

Volume: 258,078 shs
Average Volume: 147,005 shs
Market Capitalization: $10.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Stock

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NAVB Stock News Headlines

March 24, 2023 | finance.yahoo.com

Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) Q4 2022 Earnings Call Transcript

March 22, 2023 | finance.yahoo.com

Q4 2022 Navidea Biopharmaceuticals Inc Earnings Call

March 30, 2023 | Porter & Company (Ad)

Biden’s Big Lie…

Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of.

March 21, 2023 | finance.yahoo.com

Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results

March 15, 2023 | finance.yahoo.com

Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update

January 24, 2023 | reuters.com

NAVB.PH - | Stock Price & Latest News | Reuters

January 3, 2023 | msn.com

Navidea stock soars ~25% on upcoming US patent linked to cancer drug pipeline

December 28, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) Q3 2022 Earnings Call Transcript

March 30, 2023 | Porter & Company (Ad)

Biden’s Big Lie…

Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of.

November 30, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Files Appeal in CRG Case

November 28, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

November 15, 2022 | seekingalpha.com

Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call Transcript

November 14, 2022 | finance.yahoo.com

CORRECTING and REPLACING Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

November 14, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

October 5, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

September 30, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

September 27, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals, Inc. (NAVB)

September 15, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting

September 1, 2022 | markets.businessinsider.com

Navidea Biopharma To Assess Court's Judgment In Case Involving Attorney's Fees

September 1, 2022 | nasdaq.com

Navidea Opens New Sites In Phase 3 Trial In Rheumatoid Arthritis; Terminates MOU With Jubilant

September 1, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma

August 30, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update

August 18, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering

August 4, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering

August 1, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

August 1, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering

July 25, 2022 | finance.yahoo.com

Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NAVB Company Calendar

Last Earnings: 11/10/2021
Today: 3/30/2023
Next Earnings (Estimated): 5/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Diagnostic substances
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NYSEAMERICAN:NAVB
Previous Symbol: NYSEMKT:NAVB
CUSIP: 63937X10
CIK: 810509
Web: www.navidea.com
Phone: (614) 793-7500
Fax: 614-793-7522
Employees: 11
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,730,000.00
Net Margins: N/A
Pretax Margin: -13,229.31%
Return on Equity: -517.32%
Return on Assets: -322.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.60
Quick Ratio: 0.58

Sales & Book Value

Annual Sales: $530,000.00
Price / Sales: 19.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.02 per share
Price / Book: 16.00

Miscellaneous

Outstanding Shares: 32,151,000
Free Float: 17,619,000
Market Cap: $10.29 million
Optionable: Optionable
Beta: 1.36

Key Executives

Michael S. Rosol
Senior VP, Chief Executive & Medical Officer

Jeffrey G. Smith
Vice President-Operations

Erika L. Eves
Vice President-Finance & Administration

Richard McFerron
Director-Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

Group One Trading L.P.
Sold 206,900 shares on 2/9/2023
Ownership: 0.000%

View All Institutional Transactions

NAVB Stock - Frequently Asked Questions

Are investors shorting Navidea Biopharmaceuticals?: Navidea Biopharmaceuticals saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 438,500 shares, an increase of 38.2% from the January 31st total of 317,300 shares. Based on an average daily trading volume, of 150,900 shares, the days-to-cover ratio is presently 2.9 days. Currently, 2.1% of the shares of the company are short sold.
View Navidea Biopharmaceuticals' Short Interest.
When is Navidea Biopharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our NAVB earnings forecast.
How were Navidea Biopharmaceuticals' earnings last quarter?: Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) posted its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.60 million.
What other stocks do shareholders of Navidea Biopharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).

What is Navidea Biopharmaceuticals' stock symbol?: Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."
Who are Navidea Biopharmaceuticals' major shareholders?: Navidea Biopharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include John K Jr Scott and Malcolm G Witter.
View institutional ownership trends.
How do I buy shares of Navidea Biopharmaceuticals?: Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Navidea Biopharmaceuticals' stock price today?: One share of NAVB stock can currently be purchased for approximately $0.32.
How much money does Navidea Biopharmaceuticals make?: Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) has a market capitalization of $10.29 million and generates $530,000.00 in revenue each year. The biopharmaceutical company earns $-11,730,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.
How can I contact Navidea Biopharmaceuticals?: Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The official website for the company is www.navidea.com. The biopharmaceutical company can be reached via phone at (614) 793-7500, via email at ir@navidea.com, or via fax at 614-793-7522.

This page (NYSEAMERICAN:NAVB) was last updated on 3/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Navidea Biopharmaceuticals - NAVB Stock Forecast, Price & News

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Stock

NAVB Stock News Headlines

NAVB Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

NAVB Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info